clofibric acid has been researched along with Kidney Failure, Chronic in 11 studies
Clofibric Acid: An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.
clofibric acid : A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate.
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Bezafibrate treatment resulted in significant decrease in the serum concentrations of triglycerides, total cholesterol and LDL-cholesterol, whereas HDL-cholesterol serum levels increased." | 2.65 | Improvement of hyperlipidaemia by bezafibrate treatment in RDT patients. ( Grützmacher, P; Lang, W; Scheuermann, E, 1981) |
| "The evidence to support treating dyslipidemia in hemodialysis patients, however, has been mixed, with several outcome trials pending." | 2.44 | Managing dyslipidemia in chronic kidney disease. ( Harper, CR; Jacobson, TA, 2008) |
| "As a basis for establishing dosing guidelines in order to avoid side effects due to overdosage, the concentrations of total and free non-protein bound clofibrinic acid (CA) were determined before and after the administration of a single clofibrate dose (0, 2, 6, 12, 24, 48, 72, 96h) in patients with various degrees of impaired renal function and in a control group (n = 56)." | 1.27 | Serum levels of free non-protein bound clofibrinic acid after single dosing to patients with impaired renal function of various degrees--a multicenter study. ( Graben, N; Hartmann, H; Merk, W; Nikolaus, C; Schlierf, G; Schwandt, P, 1987) |
| " The recommended dosage of clofibrate is 1." | 1.26 | [Fat and renal failure--therapeutic aspects]. ( Heidland, A; Hörl, M; Hörl, WH, 1982) |
| " An individualized dosage of bezafibrate and repeated checks of the serum concentrations of the drug are recommended during long-term treatment of uremic patients." | 1.26 | Treatment of uremic hypertriglyceridaemia with bezafibrate. ( Anderson, P; Norbeck, HE, 1982) |
| " Eight of the patients had moderately impaired renal function, with a creatinine clearance between 20 and 40 ml/min; the mean plasma half-life of bezafibrate in them was 7." | 1.26 | Clinical pharmacokinetics of bezafibrate in patients with impaired renal function. ( Anderson, P; Norbeck, HE, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (81.82) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Harper, CR | 1 |
| Jacobson, TA | 1 |
| Huang, JW | 1 |
| Yen, CJ | 1 |
| Chiang, HW | 1 |
| Hung, KY | 1 |
| Tsai, TJ | 1 |
| Wu, KD | 1 |
| Robertz, GM | 1 |
| Dengler, HJ | 1 |
| Grützmacher, P | 1 |
| Scheuermann, E | 1 |
| Lang, W | 1 |
| Lacour, B | 1 |
| Di Giulio, S | 1 |
| Nicolaï, A | 1 |
| Drüeke, T | 1 |
| Debray, M | 1 |
| Boulu, RG | 1 |
| Hörl, WH | 1 |
| Hörl, M | 1 |
| Heidland, A | 1 |
| Norbeck, HE | 2 |
| Anderson, P | 2 |
| Bjornsson, TD | 1 |
| Meffin, PJ | 1 |
| Peters, FA | 1 |
| Blaschke, TF | 1 |
| Kasiske, BL | 1 |
| O'Donnell, MP | 1 |
| Garvis, WJ | 1 |
| Keane, WF | 1 |
| Merk, W | 1 |
| Graben, N | 1 |
| Hartmann, H | 1 |
| Nikolaus, C | 1 |
| Schlierf, G | 1 |
| Schwandt, P | 1 |
1 review available for clofibric acid and Kidney Failure, Chronic
| Article | Year |
|---|---|
Managing dyslipidemia in chronic kidney disease.
Topics: Algorithms; Anticholesteremic Agents; Cardiovascular Diseases; Clofibric Acid; Dyslipidemias; Fatty | 2008 |
1 trial available for clofibric acid and Kidney Failure, Chronic
| Article | Year |
|---|---|
Improvement of hyperlipidaemia by bezafibrate treatment in RDT patients.
Topics: Adult; Bezafibrate; Cholesterol; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Humans; Hyper | 1981 |
9 other studies available for clofibric acid and Kidney Failure, Chronic
| Article | Year |
|---|---|
Adiponectin in peritoneal dialysis patients: a comparison with hemodialysis patients and subjects with normal renal function.
Topics: Adiponectin; Aged; Body Mass Index; Clofibric Acid; Coronary Vessels; Diabetes Mellitus; Echocardiog | 2004 |
Endogenous ligand(s) decrease drug--protein binding in uremic sera: a fluorescence probe study.
Topics: Adult; Clofibrate; Clofibric Acid; Dansyl Compounds; Female; Fluorescent Dyes; Glycine; Humans; Kidn | 1983 |
[Study of the binding characteristics of chlorophenoxyisobutyric acid to serum proteins in chronically uremic patients : influence of dialysis and heparine (author's transl)].
Topics: Binding, Competitive; Blood Proteins; Clofibrate; Clofibric Acid; Dialysis; Heparin; Humans; In Vitr | 1982 |
[Fat and renal failure--therapeutic aspects].
Topics: Acute Kidney Injury; Animals; Bezafibrate; Carnitine; Charcoal; Clofibrate; Clofibric Acid; Humans; | 1982 |
Treatment of uremic hypertriglyceridaemia with bezafibrate.
Topics: Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipidemias; Kidney Failur | 1982 |
Clinical pharmacokinetics of bezafibrate in patients with impaired renal function.
Topics: Adult; Aged; Bezafibrate; Clofibrate; Clofibric Acid; Creatinine; Female; Humans; Hyperlipidemias; H | 1981 |
Saliva and plasma levels and plasma protein binding of clofibrinic acid in uremic patients.
Topics: Adult; Aged; Blood Proteins; Clofibrate; Clofibric Acid; Humans; Kidney Failure, Chronic; Middle Age | 1980 |
Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure.
Topics: Animals; Cholesterol; Clofibrate; Clofibric Acid; Disease Models, Animal; Glomerulonephritis; Glomer | 1988 |
Serum levels of free non-protein bound clofibrinic acid after single dosing to patients with impaired renal function of various degrees--a multicenter study.
Topics: Adult; Clofibrate; Clofibric Acid; Creatinine; Female; Humans; Kidney Failure, Chronic; Kinetics; Ma | 1987 |